Provided by Tiger Fintech (Singapore) Pte. Ltd.

Clearside Biomedical

0.8100
+0.04906.44%
Post-market: 0.7975-0.0125-1.54%19:27 EDT
Volume:501.10K
Turnover:391.17K
Market Cap:62.94M
PE:-1.99
High:0.8100
Open:0.7570
Low:0.7400
Close:0.7610
Loading ...

Clearside Biomedical Is Maintained at Buy by Needham

Dow Jones
·
28 Mar

Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
28 Mar

Clearside Biomedical Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Mar

Clearside Biomedical Reports 2024 Financial Results and Updates

TIPRANKS
·
28 Mar

Clearside Biomedical Q4 2024 GAAP EPS $(0.10), Inline, Sales $306.00K Beat $176.67K Estimate

Benzinga
·
28 Mar

Clearside Biomedical Q4 EPS USD -0.1

THOMSON REUTERS
·
28 Mar

Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
28 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Mar

Clearside Biomedical Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
26 Mar

Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

GlobeNewswire
·
24 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
24 Mar

Positive Outlook for Clearside Biomedical’s CLS-AX in Wet AMD Market with Competitive Trial Results and Flexible Dosing Strategy

TIPRANKS
·
21 Mar

Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

GlobeNewswire
·
20 Mar

Clearside Biomedical Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
07 Mar

Promising Potential of Clearside Biomedical’s CLS-AX Treatment Justifies Buy Rating

TIPRANKS
·
07 Mar

Clearside Biomedical Price Target Maintained With a $6.00/Share by Needham

Dow Jones
·
07 Mar

Analysts Conflicted on These Healthcare Names: Clearside Biomedical (CLSD) and Virpax Pharmaceuticals (VRPX)

TIPRANKS
·
07 Mar

Clearside Biomedical announces successful End-of-Phase 2 meeting for CLS-AX

TIPRANKS
·
06 Mar

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting With the FDA and Alignment on Phase 3 Plans for Suprachoroidal Cls-Ax in Wet Amd

THOMSON REUTERS
·
06 Mar

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

GlobeNewswire
·
06 Mar